Neuphoria Therapeutics (NEUP) vs Psyence Biomedical (PBM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuphoria Therapeutics (NEUP) has outperformed Psyence Biomedical (PBM) over the past year, losing 82.3% versus a loss of 97.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEUP | PBM |
|---|---|---|
| Share price | $3.36 | $4.97 |
| Market cap | $18.18M | — |
| 1-day change | +0.30% | -2.93% |
| YTD return | -13.40% | -82.59% |
| 1-year return | -82.32% | -97.05% |
| EPS (TTM) | $-3.06 | $-12.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.21 | $150.78 |
| 52-week low | $3.19 | $1.92 |
| Distance from 52-week high | -82.51% | -96.70% |
| Analyst consensus | none | — |
| Average volume | 161.66K | 94.85K |
| Shares outstanding | 5.41M | — |
| Employees | 1 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NEUP has outperformed PBM by 14.7 percentage points over the past year.
About Neuphoria Therapeutics
NEUP stock →Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
NEUP vs PBM FAQ
Which stock has performed better over the past year, NEUP or PBM?
NEUP returned -82.32% over the past 12 months, compared with -97.05% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Neuphoria Therapeutics and Psyence Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.